Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo To Analyze Protein PTMs for Boehringer Ingelheim

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies said today that it will use its mass spectrometry platform to quantitatively analyze post-translational modifications of proteins for Boehringer Ingelheim.
 
Kinaxo, a spinout of the Max-Planck Institute of Biochemistry based in Martinsried, Germany, will use its Cellular Target Profiling technology to study the effects of different compounds on proteome-wide signal transduction pathways for the drugmaker.
 
In the initial phase of the two-year agreement, the company will conduct two studies that will provide “a detailed and comprehensive picture” of in vivo mode of action in cultured cells or in animal tissue.
 
One study will analyze cell lines to measure the effects of an enzyme inhibitor on the acetylation status of the cellular proteome.
 
In a second study, Kinaxo will use its phosphoproteomics technology to compare neural tissues of wild-type and genetically modified mouse strains to identify differences in signal transduction pathway activation with the goal of identifying new drug targets.
 
The company’s PTM analysis service combines its mass spectrometry platform with stable isotope labeling by amino acids in cell culture, or SILAC, which was developed at Max-Planck.
 
Financial terms of the agreement were not released.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.